Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 1, 1998, Pages 18-26

  Von Bahr, Christer ^a   Steiner, Eugen ^b   Koike, Yuichi ^b   Gabrielsson, Johan ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; NORTRIPTYLINE; PENTOBARBITAL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG URINE LEVEL; ENZYME INDUCTION; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

ADRENERGIC UPTAKE INHIBITORS; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; GABA MODULATORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; NORTRIPTYLINE; PENTOBARBITAL; TIME FACTORS;

EID: 0031847880     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90018-2     Document Type: Article

References (42)

1. Conney A. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967;19:317-66.
2. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990;45:241-98.
3. Mellström B, Bertilsson L, Birgersson C, Göransson M, von Bahr C. E- and Z-10-hydroxylation of nortriptyline by human liver microsomes - methods and characterization. Drug Metab Dispos 1983;11:115-9.
4. Alexanderson B, Borgå O. Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses. Eur J Clin Pharmacol 1973;5:174-180.
5. Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-93.
6. von Bahr C, Birgersson C, Blanck A, Göransson M, Mellström B, Nilsell K. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver. Life Sci 1983;33:631-6.
7. Borgå O, Palmér L, Sjöqvist F, Holmstedt B. Mass fragmentography used in quantitative analysis of drugs and endogenous compounds in biological fluids. Fifth International Pharmacology Congress, Basel, 1973. p. 56-68.
8. Bertilsson L, Nordin C, Otoni K, Resul B, Scheinin M, Siwers B, et al. Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects with some observations on pharmacodynamic effects. Clin Pharmacol Ther 1986;40:261-7.
9. Garle M, Petters I. Gas chromatographic determinations of barbiturates by use of extractive alkylation and SCOT column separation. J Chromatogr 1977;140:165-9.
10. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 2nd ed. Stockholm: Swedish Pharmaceutical Press; 1997.
11. Walle T, Walle UK, Olanoff LS, Conradi EC. Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol 1986;22:317-23.
12. Gram LF, Fredricson-Overø K. First-pass metabolism of nortriptyline in man. Clin Pharmacol Ther 1975;18:305-14.
13. Gibaldi M, Perrier P. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
14. Breckenridge A, Orme M, Davies L, Thorgeirsson S, Davies D. Dose-dependent enzyme induction. Clin Pharmacol Ther 1973;14:514-20.
15. Vesell ES, Page JG. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest 1969;48:2202-9.
16. Haglund K, Seideman P, Collste P, Borg KO, von Bahr C. Influence of pentobarbital on metoprolol levels. Clin Pharmacol Ther 1979;26:326-9.
17. Spina E, Avenso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996;18:60-4.
18. Alván G, Piafsky K, Lind M, von Bahr C. Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther 1977;22:316-21.
19. Rutledge DR, Pieper JA, Mirvis DM. Effects of chronic phenobarbital disposition in humans. J Pharmacol Exp Ther 1988;246:7-13.
20. Rowland M. Influence of route of administration on drug availability. J Pharm Sci 1972;61:70-4.
21. Bertilsson L, Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma level. Eur J Clin Pharmacol 1972;4:201-5.
22. Alexanderson B, Evans DAP, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969;2:764-8.
23. Woolhouse NM, Adjepon-Yamoah KK, Mellström B, Hedman A, Bertilsson L, Sjöqvist F. Nortriptyline and debrisoquine hydroxylation in Ghanaian and Swedish subjects. Clin Pharmacol Ther 1984;36:374-8.
24. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986;22:49-53.
25. Leclercq V, Delager JP, Horsmans Y, Van Nieuwenhuyze Y, Harrengt C. Influence of rifampicin, phenobarbital and cimetidine on mixed-function oxygenase in the exclusive and poor metabolizers of debrisoquine. Int J Clin Pharmacol Ther Toxicol 1989;27:593-8.
26. Guengerich FP. Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In:Pacifici GM, Fracchia GN, editors. Advances in drug metabolism in man. Brussels: Directorate-General, Science, Research and Development; 1995, p. 179-231.
27. von Bahr C, Birgersson C, Morgan ET, Eriksson O, Göransson M, Spina E, et al. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations. Xenobiotica 1986;16:391-400.
28. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
29. Lemoine A, Gautier JC, Azoulay D, Kiffer L, Guengerich FP, Beaune P, et al. The major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
30. Døssing M, Pilsgaard H, Rasmussen B, Enghusen Pulsen H. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol 1983;25:215-22.
31. Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989;36:39-46.
32. Seideman P, Borg KO, Haglund K, von Bahr C. Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with phenobarbitone in hypertension. Br J Clin Pharmacol 1987;23:267-71.
33. Ward SA, Walle T, Walle K, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
34. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6β-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J Pharm Sci 1995;84:292-4.
35. Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time-dependent changes - autoinduction of carbamazepine epoxidation. J Clin Pharmacol 1986;26:459-62.
36. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 1996;41:477-91.
37. Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P450 gene expression. Biochem J 1992;281: 577-92.
38. Liang Q, He JS, Fulco AJ. The role of the Barbie Box sequences as cis-acting elements involved in the barbiturate-mediated induction of cytochromes P450BM-1 and P450BM-3 in Bacillus megaterium. J Biol Chem 1995;270:4438-50.
39. Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 1995;23:415-421.
40. Abramson FP. Kinetic models of induction; I: persistence of inducing substance. J Pharm Sci 1986;75:223-8.
41. Reidenberg MM, Lowenthal DT, Briggs W, Gasparo M. Pentobarbital elimination in patients with poor renal function. Clin Pharmacol Ther 1976;20:67-71.
42. Baldeo WC, Gilbert JNT, Powell JW. Multidose studies in the human metabolism of pentobarbitone. Eur J Drug Metab Pharmacokinet 1980;5:75-80.